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ABSTRACT 
The MST1R (RON) kinase is overexpressed in >80% of human pancreatic cancers, but its role 
in pancreatic carcinogenesis is unknown.  In this study, we examined the relevance of Mst1r 
kinase to Kras driven pancreatic carcinogenesis using genetically engineered mouse models. 
In the setting of mutant Kras, Mst1r overexpression increased acinar-ductal metaplasia (ADM), 
accelerated progression of pancreatic intraepithelial neoplasia (PanIN), and resulted in the 
accumulation of (mannose receptor C type 1) MRC1+, (arginase 1) Arg+ macrophages in the 
tumor microenvironment.  Conversely, absence of a functional Mst1r kinase slowed PanIN 
initiation, resulted in smaller tumors, prolonged survival and a reduced tumor associated 
macrophage content. Mst1r expression was associated with increased production of its ligand 
Mst1, and in orthotopic models, suppression of Mst1 expression resulted in reduced tumor size, 
changes in macrophage polarization and enhanced T cell infiltration. This study demonstrates 
the functional significance of Mst1r during pancreatic cancer initiation and progression.  Further, 
it provides proof of concept that targeting Mst1r can modulate pancreatic cancer growth and the 
microenvironment. This study provides further rationale for targeting Mst1r as a therapeutic 
strategy. 
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INTRODUCTION 
 Over the last several years, the genetic alterations that govern pancreatic 
carcinogenesis have been well-characterized and multiple genetically engineered mouse 
models of pancreatic cancer have been developed based on known driver mutations1-4. 
Disappointingly, however, our ability to translate these discoveries into impactful therapies 
remains slow and yet overall, less emphasis has been placed on downstream changes in gene 
and protein expression, often because these changes are dynamic, ill-defined, and therefore of 
unclear significance.  
The upregulation of MST1R tyrosine kinase expression is a molecular event of particular 
interest in many epithelial neoplasms, as it can mediate oncogenic phenotypes and addiction to 
KRAS signaling5,6.  Additionally, MST1R signaling has been shown to promote alternative 
activation of macrophages, which are potently immunosuppressive.  Thus, MST1R on tumor 
cells and in tumor-associated macrophages is potentially targetable7.  However, it remains 
unclear whether MST1R signaling actually promotes pancreatic cancer progression or if MST1R 
overexpression merely represents an epiphenomenon.   
 To address this question, we utilized mouse genetic gain and loss of function 
approaches. For Mst1r overexpression, we created a transgenic mouse strain to express Mst1r, 
in a pancreas specific manner while we used a Mst1r knock-in strain containing a targeted 
deletion of the tyrosine kinase signaling domain to study loss of Mst1r function.  These studies 
reveal that in the setting of oncogenic Kras, Mst1r accelerates pancreatic duct neoplasia and 
progression to adenocarcinoma, though it is not absolutely required, and that functional Mst1r 
kinase results in increased tumor macrophage content and changes in polarization. Mst1r 
expression was associated with increased expression of its cognate ligand, Mst1. Additional 
studies in an orthotopic model demonstrate that loss of Mst1 expression, also resulted in 
reduced tumor growth associated with macrophage polarization toward the M1 state, suggesting 
that targeting Mst1/Mst1r signaling warrants continued investigation.  
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RESULTS 
 Mst1r Expression Accelerates Pancreatic Carcinogenesis  
 To study the effects of Mst1r expression on pancreatic duct carcinogenesis, we 
developed a transgenic mouse to direct pancreas-specific expression of the wild-type Mst1r 
protein using a Mst1r murine minigene driven by the Pdx-1 promoter utilized in our Pdx-1-cre 
strain (Pdx-1-Mst1r) (Supplemental 1A)4.  Founder Pdx-1-Mst1r mice demonstrated 2-fold 
greater expression of Mst1r protein compared to normal pancreas (Supplemental 1B).  A cohort 
of 32 Pdx-1-Mst1r mice were aged to 18 months.  Fourteen animals were sacrificed at 
approximately 10 months secondary to severe dermatitis.  Pdx-1 is expressed in terminally 
differentiated keratinocytes in the spinous layer of the epidermis, suggesting that Mst1r 
overexpression in the skin of these animals resulted in dysregulated inflammation11.  No overt 
histopathologic changes were evident in the pancreata of these animals.  Remaining mice were 
sacrificed at 18 months of age.  While no overt pancreatic neoplasia developed in 17 mice, 1 
animal developed a moderately-poorly differentiated primary pancreatic ductal adenocarcinoma 
with liver metastases (Supplemental 1C-I).  Immunofluorescent staining for the epithelial marker 
CK-19 demonstrated ductal structures in both the primary pancreatic tumor and liver 
metastases (Supplemental 1H-I).  
 Since the majority of human pancreatic cancers harbor mutant Kras, we were most 
interested in studying the effects of Mst1r signaling in this setting.  Thus, Pdx-1-Mst1r mice were 
bred to LSL-KrasG12D mice to yield mice (KR), which were then bred with Pdx-1-Cre to yield the 
compound strain termed, KRC, that overexpressed Mst1r in the pancreas in the presence of 
mutant Kras.   
 Animals were sacrificed at times ranging from 6 weeks to 15 months along with aged-
matched controls (KC).  Pancreatic tissue sections were analyzed for histology and 
immunostained to characterize Mst1r expression.   Both KC and KRC strains exhibited acinar-
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ductal metaplasia (ADM) and PanIN formation (Figure 1A, B), though ADM was considerably 
more prominent in KRC mice (Figure 1C).  In wild-type mice, basal Mst1r expression was 
restricted to islets (Supplemental 2A).  In contrast, both KC and KRC strains demonstrated 
areas of Mst1r expression in ADM and PanIN lesions (Supplemental 2B), which were not 
present in wild-type pancreata.  The presence of Mst1r expression in KC animals is likely 
secondary to known upregulation of Mst1r downstream of mutant KRAS12.  In KRC mice, we 
observed an additional pattern of Mst1r expression, particularly in large lesions with extensive 
ADM.  These areas of Mst1r expression were marked by concomitant expression of nuclear 
Pdx-1 consistent with presence of the Mst1r transgene (Figure 1D).   
 We next compared age-matched KC, and KRC pancreata to determine the 
consequences gain of Mst1r function. Lesions that developed in KC mice up to 3 months were 
predominantly low grade PanIN (Figure 1E).  In contrast, by 3 months, KRC mice developed 
large, abundant foci of ADM, many of which appeared to progress directly to high grade PanIN, 
a phenomenon we rarely observed in KC pancreata (Figure 1E). These lesions demonstrated a 
2-fold increase in proliferation as assayed by Ki67 qPCR (Supplemental 2C).    At later time 
points (6-9 months), KRC pancreata consistently contained more advanced PanIN than KC 
controls (Supplemental 2D, n=6, p <0.05).  In fact, 9 month KRC pancreata were nearly 
replaced with high grade PanIN and invasive cancer, while lesions in KC pancreata remained 
predominantly low grade (Figure 1E).  The survival of KRC mice was markedly reduced as 
compared to KC animals, in which median survival was not reached (Figure 1F, 95% CI 43-51 
weeks).   While we did observe liver and lung metastases in KRC mice as early as 3 months, it 
appeared that local disease progression was the most common cause of early lethality.  Taken 
together, these results demonstrate that Mst1r accelerates both the initiation and progression of 
Kras-mediated pancreatic duct neoplasia in the mouse.   
 
Loss of Functional Mst1R Kinase Slows Progression to Pancreatic Cancer 
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After finding that Mst1R kinase overexpression results in acceleration of pancreatic duct 
neoplasia, we sought to determine if Mst1r was required for progression to pancreatic cancer. 
Loss of function studies were conducted using mice with a targeted deletion of the tyrosine 
kinase signaling domain of the receptor, Mst1r TK-/- (referred to as TK-/-), created via a knock-in-
out strategy8.  Note that while, gain of function studies were conducted on a 129/B6 hybrid 
background, loss of function studies were conducted on a pure C57/B6 background with paired 
littermates. TK-/- mice were bred to LSL-KRASG12D and Pdx-1-Cre mice ultimately, yielding  
KTK-/-C, a strain bearing pancreas specific expression of mutant Kras with a functionally inactive 
Mst1r kinase. In stark contrast to KC mice, PanIN initiation and progression was delayed in  
KTK-/-C mice.  In these mice, sparse PanIN were apparent at 3 months of age, and those that 
were present were low grade (Figure 1E).  In KTK-/-C mice, PanIN began to appear regularly at 
approximately 6 months, were predominantly low grade and these persisted well beyond 12 
months with delayed progression to invasive cancer (Figure 1E). The survival of KTK-/-C mice 
significantly exceeded that of KC littermate controls (p=0.02) (Figure 1G). While we did observe 
eventual progression to carcinoma in some animals, total pancreas weight in KTK-/-C was 
reduced by 40% (Supplemental 2E) and tumor formation in KTK-/-C was much more focal as 
compared to KC in which multiple areas of the pancreas were involved by invasive carcinoma 
(Supplemental 2F). Thus, Mst1r function is not required for, but does significantly accelerate 
progression to pancreatic cancer. 
 
Mst1r Signaling Alters Macrophage Polarization 
 In normal biology, Mst1r signaling results in attenuation of inflammation, by promoting 
changes in macrophage polarization from an “M1” and toward an “M2” state, as characterized 
by increased expression of M2 cell surface markers such as CD163 and MRC113,14. During our 
examinations of pancreatic histology from the gain and loss of function Mst1r strains, we noted 
clear differences in the immune cell infiltrates. We therefore characterized the number of F4/80+ 
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macrophages and found a marked increase in KRC pancreata compared with KC at 6 months of 
age (Figure 2A). In comparing KC to KTK-/-C mice, the difference in macrophage accumulation 
was apparent even earlier, as macrophages are almost completely absent from KTK-/-C 
pancreata until 3m of age (Figure 2B).  To more rigorously assess macrophage content, we 
examined macrophage content in the three strains using immunofluorescent double-labelling 
with F4/80+ and CD68+. This study confirmed the quantity of double labelled cells correlated 
with increasing expression of functional Mst1r kinase using strain-specific background controls 
(Supplemental 3A). We next examined the relative abundance of CD68+/CD163+ macrophages 
over time in the KC, KRC and KTK-/-C strains and noted that double-labelled cells were most 
abundant in KRC and least abundant in KTK-/-C pancreata, consistent with the relative activity of 
Mst1r kinase (Figure 2C-D and Supplemental Figure B).  
To further characterize the macrophage content, we examined pancreatic and splenic 
tissues from KC and KRC mice using multi-color flow cytometry15. We observed comparable 
infiltrates of CD45+CD11b+Gr1lo myeloid-lineage cells in KRC and KC animals, in both 
pancreatic and splenic cell suspensions (Figure 2E).  After identifying the fraction of 
CD45+CD11b+Gr-1lo infiltrating cells, we then further characterized their expression of CD11c, 
a marker of inflammatory macrophages, and MRC1, another marker of immunosuppressive, 
tumor-associated macrophages16,17.  Similar to our IHC studies, we observed the fraction of 
macrophages expressing cell surface markers indicative of an immunosuppressive phenotype 
(MRC1+) were significantly greater in KRC than in KC pancreata, while the fraction of CD11c+ 
macrophages was significantly greater in KC than in KRC pancreata (Figure 2F).  Given our 
prior observations that KC pancreata develop increasing Mst1r expression associated with 
PanIN progression, we determined the relative quantity of Mst1r expression by Q-RT-PCR in 
order to characterize the relationship of macrophage phenotype to Mst1r expression.  This 
analysis revealed that, independent of strain, high Mst1r expression was associated with a 
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significant increase in the percentage of double positive MRC1+/CD11c+ macrophages as 
compared with tissues that had low Mst1r expression (p=0.01) (Figure 2G).   
 To further characterize macrophage phenotypes, we performed immunofluorescent 
staining of KRC pancreatic tissues using the markers F4/80, MRC1, MHC II, and Arginase I.  
Staining revealed that F4/80+/MRC1+ macrophages had a distinct morphology.  These cells 
were small, round, and were frequently embedded in dense fibrous stroma surrounding the 
neoplastic cells (Supplemental Figure 4A).  Additionally, these cells expressed Arginase I, a 
functional marker of the immunosuppressive tumor-promoting macrophages (Supplemental 
Figure 4B)18.  We then stained these tissues for expression of MHCII, a marker of inflammatory 
macrophages with antigen presentation capacity17.   In contrast to MRC1+ macrophages, 
MHCII+ cells were much larger with vacuolated cytoplasm suggestive of phagocytic activity and 
antigen-presenting capability (Supplemental Figure 4C).  Multiple areas of F4/80+ cells were 
identified primarily in KRC pancreata, a result consistent with our flow cytometry data that 
demonstrated an increased number of double positive MRC1+/CD11c+ macrophages in tissues 
with high levels of Mst1r expression.  Additionally, many of these macrophages co-stained with 
Ki67, a marker of active replication (Supplemental Figure 4D).   
KPC mice have been shown to develop splenomegaly secondary to extramedullary 
hematopoiesis and accumulation of splenic CD11b+Gr1lo myeloid-derived suppressor cells18,19.  
We next analyzed the spleens of KRC and KC animals and observed a similar pattern of 
CD11b+Gr1lo expression.  However, we did not observe any accumulation of either CD11c+ or 
MRC1+ macrophages in the spleen of KRC or KC animals, strongly suggesting that the 
differentiation of these macrophages is a result of soluble factors present within the tumor 
microenvironment (Supplemental Figure 4E).  
 
Mst1-Mst1r Signaling Attenuates the M1 Macrophage State, But Does Not Independently 
Drive M2 Differentiation In Vitro  
 9
 To further investigate if the alterations in macrophage phenotype observed were due to 
Mst1r signaling, we next examined if ligand-induced Mst1r activation was capable of altering 
macrophage polarization in vitro.  Bone marrow-derived macrophages were treated with either 
Mst1r ligand, Mst1, or tumor conditioned media from a murine pancreatic cancer cell line, LMP, 
that expresses Mst1r20.  Macrophages were treated with either IL-4 to polarize toward the 
immunosuppressive “M2” state (measured by expression of TGF-β and Arginase-1) or IFN-γ 
LPS to induce an inflammatory “M1” state (measured by expression of IFN-γ, IL-12β, and 
inducible nitric oxide synthase (iNOS)21.  Mst1 stimulation inhibited the expression of IFN-γ IL-12 
and iNOS but did not induce expression of Arginase I or TGF-β (Figure 3A, B).  Thus, in this 
experimental setting, exposure to Mst1 strongly attenuated inflammatory M1 polarization, but 
did not fully induce an immunosuppressive M2 phenotype. LMP conditioned media, however, 
was capable of inducing M2 differentiation (Figure 3B), suggesting that signals in addition to 
Mst1r activation are required to fully drive polarization toward the M2 phenotype.  
 
Mst1r Activates an Autocrine/Paracrine Positive Feedback Loop 
 We next sought to determine how Mst1r signaling in the epithelial tumor cell was 
effecting changes in macrophage state in the pancreatic tumor microenvironment.  Given the 
effects of Mst1 on macrophage polarization, we hypothesized that Mst1r overexpression may in 
fact result in upregulation of Mst1 expression and secretion.  To explore this, we derived 
multiple epithelial cell lines from tumors arising in KC and KRC pancreata and characterized 
their Mst1r and Mst1 expression by Q-RT-PCR.  These studies revealed that Mst1r expressing 
lines demonstrated 10- to 60-fold increases in Mst1 expression as compared to Mst1r negative 
lines (Figure 4A). Additionally, we used a luciferase reporter assay to interrogate whether the 
Mst1r promoter was activated in response to Mst1 stimulation in multiple murine pancreatic 
cancer cell lines (PanIN 4313 and LMP).  We found a significant increase in Mst1r transcription 
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when stimulated with Mst1, with a positive regulatory response element located between -335 
and -485 bp within the Mst1r promoter (Figure 4B, C).  We similarly observed an increase in 
Mst1r transcript after bone marrow derived macrophages were exposed to Mst1 (Figure 4D). 
Immunostaining for Mst1 in pancreatic tissues confirmed Mst1 expression in epithelial cells with 
increased frequency/intensity in KRC vs. age-matched KC mice (Figure 4E).  Finally, we 
screened tissue lysates for Mst1 protein levels and found significantly higher levels of Mst1 
during disease progression (Supplemental 5A,B). Together, these data suggest that increased 
Mst1r expression results in increased expression of Mst1 by both pancreatic cancer cells and 
macrophages. 
 
Mst1/Mst1r Knockdown Significantly Inhibits Tumor Growth In Vivo 
 To further test the hypothesis that Mst1r signaling from the epithelial tumor cell 
influences the tumor microenvironment, we utilized lentiviral shRNA to achieve knockdown of 
Mst1 expression in murine LMP cells (Figure 5A). The LMP pancreatic cancer cell line, derived 
from liver metastases of KPC mice, is highly tumorigenic when xenografted into the pancreata 
of syngeneic B6/129 F1 hybrid mice20.  While Mst1 deficient cells were able to proliferate in 
vitro,  they did proliferate more slowly than Mst1 intact cells (Supplemental 5C). Both lines were 
able to form tumors after orthotopic injection, however there was a profound reduction in tumor 
size from Mst1 deficient versus Mst1 intact lines (Figure 5B). We next performed flow cytometry 
on these tumors to determine the ratio of F4/80+/CD11c+ to F4/80+/MRC1+ expressing 
macrophages. Notably, the number of MRC1+ macrophages was markedly reduced in Mst1 
deficient LMP tumors (p=0.03), suggesting that Mst1 secreted into the tumor microenvironment 
modulates macrophage polarization (Figure 5C). In orthotopic tumors, immunostaining for CD3+ 
T cells revealed marked infiltration throughout Mst1 deficient tumors, as compared to controls in 
which T cells were observed nearly exclusively at the periphery (Figure 5D). When we repeated 
this experiment in immunodeficient NSG mice, Mst-1 deficient tumors grew faster causing 
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earlier lethality (data not shown), suggesting that an adaptive immune response was at least in 
part, responsible for growth suppression in the absence of Mst1-Mst1r signaling.   Together, 
with our prior findings, these results suggest that Mst1r expression by pancreatic cancer cells 
results in secreted Mst1 protein that is then available to initiate autocrine and paracrine 
signaling within the tumor microenvironment (Figure 6A).   
 
Mst1r Expression Correlates with Increased Ccl2 Secretion by Pancreatic Cancer Cells  
Finally, we took advantage of the LMP Mst1/Mst1r knockdown cell lines to try and 
identify chemokines which may mediate the Mst1r related accumulation of 
macrophages in the pancreatic tumor microenvironment.  We performed an ELISA to 
measure cytokine/chemokine levels on conditioned media from LMP control and 
knockdown cells. This revealed that an 8 fold reduction in the level of Ccl2 in the 
absence of Mst1/Mst1r expression (Figure 5E). To further evaluate this finding, we 
assayed for mRNA levels of Ccl2 in 3 month old pancreata from KRC and KTK-/-C mice. 
This confirmed a greater than 2 fold reduction in Ccl2 mRNA in KTK-/-C versus KRC 
mice (Figure 5F). As Ccl2 has been shown to mediate localization of bone marrow 
derived monocytes to the pancreatic tumor microenvironment, these findings suggest 
Mst1r mediated secretion of Ccl2 is at least partially responsible for our observations 
that macrophage content correlated with the level of functional Mst1r signaling22,23. 
 
MST1R Expression Is Associated With Poor Outcomes in Human Pancreatic Cancer 
 To determine whether our findings regarding the relevance of Mst1r signaling in the 
mouse were relevant to human disease, we examined gene expression data from two 
independent cohorts. We first analyzed a publicly available dataset containing a gene 
expression profiling of 125 human primary pancreatic cancers and 46 normal pancreas 
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(GSE71729). We confirmed MST1R overexpression in cancers compared with normal pancreas 
(data not shown). Interestingly we found that patients with a high expression of MST1R had a 
significantly worse overall survival (p = 0.0285). Analysis of the TCGA’s pancreatic cancer 
cohort confirmed the association between high MST1R expression and poor overall survival (p 
= 0.0009) and also revealed that high expression of MST1R was associated with poorer 
disease-free survival (p < 0.0001) (Figures 6B,C).    
 
DISCUSSION 
 The MST1R kinase is overexpressed in human pancreatic cancer yet its contribution to 
pancreatic carcinogenesis remains unknown.  In this study, we examined the consequences of 
gain and loss of Mst1r function in genetically engineered mouse models of pancreatic 
carcinogenesis initiated by mutant KRAS, widely accepted as a relevant model of human 
disease.  Mst1r gain and loss of function each modulated pancreatic carcinogenesis, resulting in 
significant changes in survival.   Mst1r associated carcinogenesis was marked by: 1) earlier 
onset of ADM that appears to progress rapidly to high-grade PanIN, 2) More rapid progression 
to invasive cancer, and 3) modulation of the immune microenvironment toward a tumor 
permissive phenotype.   
 Given the predominantly embryologic expression of the Pdx-1 promoter, the initial 
degree of Mst1r overexpression in the KRC compound strain is modest.  As expected, we 
identified a progressive increase in Mst1r expression in KC mice, consistent with its putative role 
as a Kras effector6.  The increasing expression of Mst1r in Kras mutant mice is important to 
highlight because they bias the experimental results towards the null hypothesis, when 
comparing KRC to KC mice, making the differences we observed more noteworthy.  It is clear 
from our studies, however, that while Mst1r promotes disease progression in the setting of 
oncogenic Kras, it is not absolutely required for pancreatic carcinogenesis.  In loss of function 
studies, we observed an obvious delay in disease progression and a modest, though statistically 
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significant improvement in survival.  Concordant with these findings, we observed a smaller 
tumor burden in the absence of Mst1r kinase activity. Importantly, mining of two independent 
databases revealed that high levels of Mst1r expression are a poor prognostic factor for survival 
in pancreatic cancer patients.  These findings are in contrast to a prior report that failed to find 
MST1R prognostic for survival24.  This disparity may be at least partially explained by some 
differences in methodology between the studies.  The prior study initially characterized MST1R 
expression by immunohistochemistry using an antibody that we have found to bind off-target 
antigens. The IGCC mRNA data from this study, as the authors acknowledged, also had short 
follow-up at the time of their analysis.  
 Studies in other tumor types have similarly found that MST1R signaling impacts tumor 
progression9,25-27. One purported mechanism by which MST1R impacts tumor progression is via 
its expression on macrophages within the tumor microenvironment.  MST1R signaling in 
peritoneal macrophages has been shown to drive macrophages away from immune-surveillance 
(the so-called “M1” state) towards an alternative, tumor-promoting “M2” phenotype via a 
mechanism that involves attenuation of iNOS and increased expression of Arginase-17,8,13,14.  
We therefore hypothesized that in addition to its effects on the epithelial tumor cell, MST1R 
signaling may affect pancreatic carcinogenesis indirectly by altering the polarization of infiltrating 
myeloid cells and/or tissue resident macrophages in the tumor microenvironment towards a 
tumor-promoting, immunosuppressive phenotype.   
 In keeping with this, we show that Mst1r overexpression in murine epithelial tumor cells 
is associated with upregulation of its own ligand, Mst1.  These results are consistent with recent 
studies documenting tumor cell specific MST1 upregulation in both mouse and human prostate 
cancer28,29.  We further found that Mst1 induces activation of the Mst1r promoter. To our 
knowledge, this reciprocal signaling between Mst1r expression and its own ligand, Mst1, has not 
been described. This finding that Mst1r signaling enhances Mst1 expression and that 
conversely, Mst1 knockdown is associated with decreased Mst1r expression, demonstrates the 
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presence of a feed forward signaling loop leading both to an autocrine effect on Mst1r-
expressing tumor cells, as well as a paracrine effect on Mst1r expressing macrophages within 
the tumor microenvironment. In the macrophage, Mst1-Mst1r signaling attenuates the 
expression of genes associated with tumor surveillance7.  Since we observed that Mst1 
stimulation is capable of attenuating the M1 phenotype, but not inducing the M2 state, this 
suggests that additional signals are necessary for this transition. Pancreatic cancer cell 
conditioned media was capable of inducing the M2 phenotype in vitro, also indicating that there 
are additional soluble factors secreted by tumor cells that influence macrophage state in the 
microenvironment.  Among these, one report implicated lactate as a mediator of the M1-M2 
transition30. The resultant skew towards the M2 phenotype is associated with increased 
expression of Arginase-I.  Interestingly, increased metabolism of L-arginine is associated with 
the accumulation of ornithine and proline, precursors of collagen synthesis31.  Histologically, we 
observed that most MRC1+ macrophages were embedded in dense stromal compartments 
characterized by abundant collagen deposition.  In contrast, classically activated MHCII+ 
macrophages were not surrounded by stroma and maintained a large phagocytic phenotype 
consistent with their role as antigen-presenting cells.  These results raise the possibility that the 
accumulation of alternatively activated macrophages within the tumor may result in increased 
arginine metabolism and collagen deposition, potentially contributing to the profound 
desmoplasia observed in the pancreatic cancer microenvironment. Our findings are consistent 
with those recently reported in a study that dissected the relative contribution of tissue resident 
versus bone marrow derived macrophages to pancreatic tumor progression. In this study, it was 
the F4/80+MHClow subset of macrophages which were most often tissue derived, that were 
associated with tumor progression and fibrosis32. Consistent with this study, we found that 
F4/80+/MRC1+ macrophages frequently co-express Ki67, and therefore acquire and maintain 
the ability to proliferate alongside cancer cells.  Our studies also suggest that Mst1r signaling in 
pancreatic cancer cells results in secretion of Ccl2, a ligand for the Ccr2 receptor. Ccl2 has 
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been shown to mediate trafficking of bone marrow derived monocytes to the pancreatic tumor 
microenvironment and influence tumor progression and prognosis22,23. Our findings are also 
consistent with the findings of Gardner et al. who noted a correlation of Ccl2 in a liver injury 
model33.  
 These results provide evidence of a positive feedback autocrine and paracrine Mst1-
Mst1r signaling axis, and thereby suggest that targeting the Mst1-Mst1r axis may not only have 
a direct effect on the tumor cell but may have the added benefit of therapeutic 
immunomodulation within the tumor microenvironment. In the rapidly evolving field of cancer 
immunotherapy, targeting activities of the tumor-associated macrophage has emerged as one 
central therapeutic arm of investigation. The two primary strategies have been; 1) to modulate 
the activation state of the macrophage, and 2) exclusion of the macrophage from the tumor 
microenvironment. Successful modulation of macrophage phenotypes will require a thorough 
understanding of the signals driving activation states. Our data suggests Mst1r signaling may 
contribute to this modulation in the pancreatic cancer microenvironment and is therefore worthy 
of further study as an immunomodulatory strategy in this disease.  
 
MATERIALS and METHODS 
Mice 
Animal protocols were approved by the UCSD Institutional Animal Care and Use 
Committee.  PDX-1-cre, KrasLSLG12D and the Mst1r kinase deficient strain, (TK-/-) were described 
previously4,8.  PDX-1-Mst1r animals were generated by insertion of a murine Mst1r mini-gene 
coding for wild type Mst1r protein under the control of the PDX-1 promoter9. PDX-1-Mst1r mice 
were screened for their pancreatic expression of Mst1r by western blot (Supplemental 1A,B).  
Mice with 2-fold increase in Mst1r were propagated forward.  All strains were C57BL/6J except 
for the KrasLSLG12D, (B6/129S4). All experiments used littermate control mice and equal 
numbers of each gender. C57BL/6J/129S4 F1 hybrid mice were used for orthotopic implantation 
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experiments. For animal studies group sizes were calculated by power analyses based on 
preliminary experiments using a significance level of 5% and a power of 80%. Animals were 
randomly assigned to experimental groups. The investigators were not blinded to allocation 
during experiments and outcome assessments. For genetically engineered mouse studies, 
equal numbers of male and female animals were used. Orthotopic experiments used male mice, 
aged 6-8 weeks. 
 
Generating Epithelial Cell Lines 
Pancreatic tissues were harvested from KrasCre (KC) and KrasRonCre (KRC) mice.  
Tissue fragments were embedded in Matrigel coated dishes and incubated at 37C.  Epithelial 
cells were isolated and propagated by clonal expansion. Mst1r knockdown and control lines 
were generated using shRNAs from Open Biosystems (Thermo Scientific) for mouse Mst1r, 
mouse Mst1 or scrambled control in the lenti pLKO.1 vector (Supplemental Table 1).  Clones 
were isolated and analyzed for knockdown by Q-RT-PCR (Supplemental Table 2) and western 
blot (Anti-Mst1 Abcam, 1:3000 dilution). 
Single Cell Suspensions 
After sacrifice, intra-cardiac perfusion was performed with cold PBS.  The body and tail 
of the pancreas were uniformly used for flow cytometry.  The pancreatic head was placed in 
10% saline-buffered formalin and paraffin embedded for histology.  The body and tail were 
minced into 1-2mm pieces in dissociation buffer.  Single cell suspensions were incubated at 
37oC for 15 min and then passed through a 70uM filter into separation buffer containing EDTA.  
Cells were spun, counted and viability determined on a coulter counter.   
Histology  
Tissue sections were fixed overnight in 10% NBF and transferred to 70% ethanol. 
Paraffin embedding and cutting of tissue sections was performed by the UCSD Histology Core.  
Slides were baked overnight at 60C and then either hematoxylin and eosin stained or 
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processed for immunohistochemistry/immunofluorescence. Slides were cover-slipped with 
Permount (Fisher Scientific) and stored at room temperature. Antibodies/dilutions for are 
detailed in Supplemental Table 3. 
Flow Cytometry 
Cell pellets were re-suspended in 0.5% BSA in PBS.  1x106 cells were stained with 
fluorochrome conjugated antibodies at 4C for 30 minutes.  Cells were rinsed with 2mL cold 
PBS and spun at 1500 rpm to pellet.  Supernatant was removed and the cells were re-
suspended in 200uL of stabilizing fixative.  Aqua Live/Dead Stain (Invitrogen) was used to 
exclude dead cells from the analysis.  2uL of BD Fc Block per tube was added and incubated at 
room temperature for 5 minutes prior to adding antibodies. Cells were analyzed on a Canto 
RUO Analyzer or FACS Aria Sorter equipped with 488 Argon, 633 Hene, and 405 Violet Lasers.  
Analyses were performed using FlowJo software in consultation with the UCSD/VA Research 
Flow Cytometry Core. 
Bone marrow derived macrophage experiments 
Primary murine macrophages were generated by flushing the bone marrow from the femur and 
tibia of C57BL/6 mice, followed by incubation for 5 days in DMEM containing 10% FBS and 10 
ng/mL murine M-CSF (Peprotech). BMMs were subsequently cultured in DMEM containing 2% 
serum in the presence or absence of murine recombinant M-CSF (Peprotech) for 24 hours.  
Macrophages were then stimulated for 24h with relevant ligands and then cells were lysed and 
RNA prepared using the RNAeasy Kit (Qiagen). 
Quantitative RT-PCR (Q-RT-PCR) 
RNA was extracted from pancreata using Trizol (Invitrogen) and quality checked by gel 
electrophoresis. Cell lines were plated to achieve 90% confluency.  Treatment groups included 
DMEM Complete alone or DMEM Complete with 100ng/ml recombinant murine Mst1 (R&D 
6244-MS).  Cells were incubated for the indicated times or overnight, after which time RNA was 
isolated using Trizol, then treated with DNAase1 (Invitrogen). 
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  cDNA was synthesized from 1 µg of RNA using iScript cDNA Synthesis Kit (BioRad). Q-
RT-PCR was performed using SoFast EvagGreen Supermix (BioRad) with cDNA corresponding 
to 50ng of total RNA and 500nM primers in a 20µl volume.   Primers (sequences detailed in 
Supplemental Table 2) were examined by gel electrophoresis then sequenced. Relative fold 
change was calculated using the 2-∆∆Ct method with actin used to normalize. Either an untreated 
cell line, normal pancreas or KCE 329 cell line was used as the calibrator to generate the fold 
change10.  Significance was set at 1.5-fold above or below the reference sample.  
Orthotopic Experiments   
6-8 month old F1 Hybrid male mice (B6129SF1/J mice, Jackson Laboratories, ME) were 
injected with 700,000 LMP cells into the pancreas using a 29G 1/2cc syringe.  Tumors 
originating from the injection were allowed to grow for 3.5 weeks.  Mice were then euthanized 
with the tumor removed and either fixed in 10% NBF, homogenized in Trizol (Life Technologies, 
CA) for RNA extraction or flash frozen in liquid Nitrogen and stored at -80oC for future 
processing. 
Gene expression analyses 
The GSE71729 dataset was downloaded from the Gene Expression Omnibus (GEO; 
http://www.ncbi.nlm.nih.gov/gds). The dataset corresponds to an Agilent human whole-genome 
4x44K microarray (Agilent Technologies) and contains gene expression profiling for 46 normal 
pancreas specimens and 125 pancreatic cancers with matching clinical information. TCGA 
RNAseqV2 normalized expression values have been downloaded from the Genetic Data 
Commons Data Portal (https://portal.gdc.cancer.gov). 99 samples from the TCGA cohort with 
Mst1r expression values and clinical annotation were utilized for survival analysis. Selected 
samples show consistent OS time and status regarding clinical annotations retrieved from 
TCGA and Cbioportal websites (difference in median OS time <0.2 month). Survival curves and 
associated statistics were generated using GraphPad Prism. Patient stratification corresponding 
to high and low expression was performed using Cutoff Finder (http://molpath.charite.de/cutoff/). 
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P-values refer to log-rank tests for survival curves and to unpaired t-test with Welch’s correction 
for boxplot. 
Statistics 
 Data was analyzed using Student’s t test and ANOVA where appropriate.  Survival 
analyses were performed using the Kaplan-Meier method.  Flow cytometry data was analyzed 
using the nonparametric Kruskal-Wallis test.  The Spearman’s rho coefficient was calculated for 
all correlations.  All statistical tests were 2-sided, and p-values are reported where appropriate.  
Microsoft Excel, GraphPad Prism 5, and SPSS Statistical software were used for the analyses.   
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FIGURE LEGENDS 
Figure 1. Mst1r Promotes Pancreatic Cancer Initiation and Progression 
(A) Low grade PanIN in a 6m KC mouse (B) Expansive PanIN formation in 6m KRC mouse.  (C) 
Immunofluorescent staining for amylase (red, acini) and CK19 (green, ductal epithelium), 
confirming ADM within lesions of KRC pancreata (arrows).  (D) Representative section from 6m 
KRC pancreas demonstrating sporadic areas of increased Mst1r expression (red) that correlate 
with nuclear expression of Pdx-1 (green), indicating the presence of the Pdx-1-Mst1r transgene.  
(E)  Representative sections of KC, KRC and KTK-/-C pancreata demonstrates that KRC 
develop earlier onset of high grade PanIN2 and 3 compared to KC controls and KTK-/-C 
pancreata.  (F) KRC animals have decreased survival compared with KC controls.  Median 
survival 47 weeks (95% confidence interval 43-51 weeks) KC littermates failed to reach median 
survival in this cohort, p=0.004.  (G) KTK-/-C animals have increased survival compared with KC 
controls.  Median survival 63 weeks in KTK-/-C animals vs. 53 weeks in KC animals p=0.02 
(Log-rank (Mantel-Cox) test). 
 
Figure 2.  Mst1r Effects Composition of the Immune Cell Infiltrate  
(A) Representative immunofluorescent staining of 6m KC and KRC mice revealing an increased 
infiltrate of F4/80+ cells (red) in KRC pancreata.  (B) Immunohistochemistry from 6 week 
animals demonstrating the reduced F4/80+ cell infiltrate in KTK-/-C compared to KC pancreata. 
Quantitation revealed a significant reduction in F4/80 positive cells in KTK-/-C pancreata p=0.01 
(C) Fluorescence double labelling for CD68/CD163 demonstrates an increase in KRC versus 
KC and KTK-/-C pancreata at multiple timepoints. (D) The average number of CD68/CD163 
double labelled cells from KC, KRC and KTK-/-C were quantitated revealing an increasing 
number of double labelled cells with functional Mst1r overexpression at multiple timepoints, and 
a relation to strain by 2way ANOVA, p<0.0001. 
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(E) Pancreatic tissues were analyzed with flow cytometry.  KRC and KC pancreata 
demonstrated a comparable infiltrate of CD11b+ Gr1low cells.  (F) 12m pancreata from KRC, KC 
and KTK-/-C mice analyzed by flow cytometry.  Note the predominance of CD45+ CD11b+ Gr1low 
CD11c- MRC1+ macrophages in KRC compared to the KC and KTK-/-C animals.  The 
percentage of CD45+ CD11b+ Gr1low MRC1+ macrophages present in the 12m pancreata from 
the KRC, KC and  
KTK-/-C animals analyzed by flow is represented (One-way ANOVA p=0.003).  (G) 9m 
pancreata were analyzed for expression of Mst1r by qRT-PCR.  Pancreata with high levels of 
Mst1r expression, regardless of strain, showed an increased percentage of CD45+ CD11b+ 
Gr1low CD11c+ MRC1+ cells compared to pancreatic tissues with low Mst1r expression (p=0.01).  
Data represents frequencies of gated cell populations, means were compared with non-
parametric Kruskal-Wallis Test. 
 
Figure 3.  Mst1r-Mst1r Signaling Attenuates M1 Differentiation, but does not 
Independently Drive M2 Differentiation In Vitro 
Bone marrow derived myeloid cells were isolated and treated with either IL-4 or IFN-g to induce 
M1 or M2 macrophage polarization, respectively. Cells were treated with either Mst1, LMP 
conditioned media, or a combination of both Mst1 and LMP conditioned media.  Cytokine 
expression was assayed by qRT-PCR (A) Mst1 attenuated M1 macrophage polarization, shown 
by decreased INFγ, IL-12b and iNOS.  (B) Mst1 did not independently induce M2 polarization, 
as it failed to induce expression of Arginase-I or TGFβ.  LMP-conditioned media was capable of 
inducing M2 macrophage differentiation.  Data reflect mean fold change +/- SEM. 
 
Figure 4. Mst1r Signaling Upregulates Mst1 Expression 
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(A) KRC and CK epithelial cell lines derived from KC and KRC pancreata were screened for 
their relative expression of Mst1r and Mst1 by qRT-PCR.  High levels of Mst1r expression 
correlated with similarly high levels of Mst1 expression in 3 out of 4 KRC epithelial cell lines.  
(B&C) Luciferase reporter assay results from murine pancreatic cell lines PanIN 4313 and 4964 
LM.  Cells were stimulated with 250ng/ml of Mst1 for 24-48h. A regulatory response element 
was located between -335bp and -485bp within the Mst1r promoter (p<0.0001, p =0.002).  (D) 
Bone marrow-derived macrophages were exposed to 100 ng/mL Mst1 or vehicle. Q-RT-PCR 
demonstrated a significant increase in Mst1r transcript after Mst1 (p< 0.05). (E) Immunostaining 
in 9m pancreata demonstrate increased Mst1 expression in high grade PanIN lesions in KRC 
versus KC mice. 
 
Figure 5.  Mst1/Mst1r Regulates Orthotopic Pancreatic Cancer Growth 
 (A)  shRNA knockdown resulted in ~90% reduction in Mst1 expression in LMP cells compared 
to control. B) Mst1 KD tumors weighed significantly less than control tumors (p<0.001). (C) Flow 
cytometry was performed on single cell suspensions derived from LMP control or Mst1 
knockdown tumors. Flow sorting demonstrated a reduction in MRC1+/CD11b+Grl- cells derived 
from Mst1 knockdown tumors, p=0.03. (D) Immunostaining for CD3 in LMP and LMP Mst1 KD 
tumors reveal an increase in CD3+ cells in the LMP Mst1 KD compared to the control LMP-
derived tumors. (E) Multiplex ELISA assay of conditioned media from LMP control versus LMP 
Mst1 knockdown cell lines revealed an 8 fold reduction in Ccl2. (F) Q-RT-PCR for Ccl2 in 3 and 
6 month old KRC and KTK-/-C pancreata demonstrated greater than 2 fold reduction in 
expression in the absence of functional Mst1r kinase. 
 
Figure 6.  Mst1r Activates a Feed-Forward Autocrine-Paracrine Signaling Loop that 
Effects Tumor Growth and Survival 
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(A) Model suggesting that Mst1r overexpression results in increased Mst1 and increased Ccl2 
within the tumor microenvironment, contributing to the attenuation of M1 differentiation and 
skewing macrophages towards an alternative tumor-promoting M2 state.  (B&C) Analysis of the 
TCGA’s pancreatic cancer cohort revealed the association between high MST1R expression 
and both poor overall (p = 0.0009) and disease-free survival (p < 0.0001).   
 
 






